Vectus Biosystems

Vectus Biosystems Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Vectus Biosystems (VBS.AX) as of Nov 5, 2026 is -47,691.93. In the previous year, Cash Conversion Cycle (CCC) was -14,211.19 — a change of 235.59% (lower).

Cash Conversion Cycle

-47,691.93

YoY

235.59%

Last updated:

Cash Conversion Cycle (CCC) of Vectus Biosystems is 2026 -47,691.93 . Cash Conversion Cycle (CCC) of Vectus Biosystems was 2025 -14,211.19 . It decreases by 235.59% lower compared to the previous year.

The Vectus Biosystems Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
-18,574.45 AUD
Jan 1, 2020
-10,478.04 AUD
Jan 1, 2021
-339.82 AUD
Jan 1, 2022
-3,962.50 AUD
Jan 1, 2023
-1,690.06 AUD
Jan 1, 2024
-1,154.43 AUD
Jan 1, 2025
-14,211.19 AUD
Jan 1, 2026
-47,691.93 AUD
The Vectus Biosystems Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-47,691.93+235.59%
-14,211.19+1,131.02%
-1,154.43-31.69%
-1,690.06-57.35%
-3,962.50+1,066.07%
-339.82-96.76%
-10,478.04-43.59%
-18,574.45+1.63%
-18,276.60+574.66%
-2,709.03+1,038.06%
-238.04—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectus Biosystems Stock analysis

What does Vectus Biosystems do? Vectus Biosystems Ltd. generates revenue through the development and commercialization of pharmaceutical products targeting fibrotic diseases and hypertension. The company focuses on VB0004, a compound designed to treat tissue hardening and high blood pressure, alongside candidates for fibrotic liver conditions like NASH and pulmonary fibrosis. Its subsidiary Accugen Pty Limited offers the Accugen platform, which provides qPCR reagents and software for accurate DNA and RNA quantification in laboratory testing. The primary buyers of these products are pharmaceutical companies and research institutions seeking advanced drug development tools and therapies for fibrotic disorders. Vectus Biosystems targets the medical research and development sector, specifically addressing unmet needs in fibrotic disease treatment. The Accugen platform serves laboratories requiring efficient molecular analysis tools, with its technology enhancing the speed and precision of qPCR testing. The company’s revenue streams are derived from both therapeutic product development and the sale of diagnostic solutions to biotech firms and academic research entities. The firm’s focus on fibrosis-related treatments, including heart, kidney, and liver diseases, positions it within niche therapeutic segments. Accugen’s reagents and software are sold to laboratories as part of the qPCR workflow, supporting drug discovery processes. Pharmaceutical companies and research organizations are the key segments purchasing Vectus Biosystems’ products for their R&D pipelines and clinical applications. Vectus Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectus Biosystems stock

Cash Conversion Cycle (CCC) of Vectus Biosystems is -47,691.93 in 2026.

Cash Conversion Cycle (CCC) of Vectus Biosystems changed from -14,211.19 to -47,691.93, representing a 235.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Vectus Biosystems since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Vectus Biosystems with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Vectus Biosystems

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Vectus Biosystems